BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21528848)

  • 1. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
    Hayashi R; Tanoue K; Durell SR; Chatterjee DK; Jenkins LM; Appella DH; Appella E
    Biochemistry; 2011 May; 50(21):4537-49. PubMed ID: 21528848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
    Yamaguchi H; Durell SR; Feng H; Bai Y; Anderson CW; Appella E
    Biochemistry; 2006 Nov; 45(44):13193-202. PubMed ID: 17073441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.
    Yamaguchi H; Durell SR; Chatterjee DK; Anderson CW; Appella E
    Biochemistry; 2007 Nov; 46(44):12594-603. PubMed ID: 17939684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.
    Chuman Y; Yagi H; Fukuda T; Nomura T; Matsukizono M; Shimohigashi Y; Sakaguchi K
    Protein Pept Lett; 2008; 15(9):938-48. PubMed ID: 18991770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate specificity of the human protein phosphatase 2Cdelta, Wip1.
    Yamaguchi H; Minopoli G; Demidov ON; Chatterjee DK; Anderson CW; Durell SR; Appella E
    Biochemistry; 2005 Apr; 44(14):5285-94. PubMed ID: 15807522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPM1D regulates p21 expression via dephoshporylation at serine 123.
    Cao R; Zhang J; Zhang M; Chen X
    Cell Cycle; 2015; 14(4):641-7. PubMed ID: 25590690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development.
    Hickson JA; Fong B; Watson PH; Watson AJ
    Mol Reprod Dev; 2007 Jul; 74(7):821-34. PubMed ID: 17219434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants and mutations of PPM1D control the response to DNA damage.
    Dudgeon C; Shreeram S; Tanoue K; Mazur SJ; Sayadi A; Robinson RC; Appella E; Bulavin DV
    Cell Cycle; 2013 Aug; 12(16):2656-64. PubMed ID: 23907125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites.
    Rossi M; Demidov ON; Anderson CW; Appella E; Mazur SJ
    Nucleic Acids Res; 2008 Dec; 36(22):7168-80. PubMed ID: 19015127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
    Lu X; Nguyen TA; Donehower LA
    Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical Features Important for Activity in a Class of Inhibitors Targeting the Wip1 Flap Subdomain.
    Tagad HD; Debnath S; Clausse V; Saha M; Mazur SJ; Appella E; Appella DH
    ChemMedChem; 2018 May; 13(9):894-901. PubMed ID: 29476592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatase assay for multi-phosphorylated substrates using phosphatase specific-motif antibody.
    Chuman Y; Iizuka K; Honda T; Onoue H; Shimohigashi Y; Sakaguchi K
    J Biochem; 2011 Sep; 150(3):319-25. PubMed ID: 21558087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
    Kamada R; Kudoh F; Yoshimura F; Tanino K; Sakaguchi K
    J Biochem; 2017 Oct; 162(4):303-308. PubMed ID: 28486685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
    Lu X; Nannenga B; Donehower LA
    Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
    Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
    Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
    Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
    Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
    Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the Wip1 phosphatase and its effects on the stress response.
    Lowe J; Cha H; Lee MO; Mazur SJ; Appella E; Fornace AJ
    Front Biosci (Landmark Ed); 2012 Jan; 17(4):1480-98. PubMed ID: 22201816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
    Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
    Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.